Medtronic News

Medtronic's Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure

MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) --

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco. Transcatheter Cardiovascular Therapeutics (TCT) is the world's largest educational meeting specializing in interventional cardiovascular medicine.

TCT 2011 includes a host of clinical updates on a range of Medtronic devices, some of which are investigational in the United States:*

- Resolute*(R)* and Endeavor*(R)* Zotarolimus-Eluting Coronary Stents*
- Assurant*(R)* Cobalt Iliac Balloon-Expandable Stent and Complete SE*(R)* (Self-Expanding) Vascular Stent
- IN.PACT(TM) Drug-Eluting Balloons*
- CoreValve(R) System Transcatheter Aortic Valve*
- Endurant*(R)* AAA Stent Graft
- Symplicity*(R)* Renal Denervation System*

"TCT enables us to showcase our unmatched portfolio of cardiovascular devices and the clinical data that support their use to physicians from around the world who specialize in interventional cardiovascular medicine," said Michael J. Coyle, executive vice president of Medtronic, Inc., and president of the Cardiac and Vascular Group at Medtronic. "This annual meeting presents an excellent opportunity for meaningful interactions and substantive discussions with leading clinicians and researchers about the present and future of this exciting medical field."

Oral presentations related to Medtronic products are listed chronologically below in U.S. Pacific Standard Time. These include presentations related to the company's peripheral stents on Monday; drug-eluting coronary stents, aortic stent grafts and renal denervation system on Tuesday; and drug-eluting balloons on Thursday. The CoreValve System is the subject of multiple presentations Monday through Thursday. In addition, the late-breaking clinical trials session on Friday includes TWENTE, a head-to-head comparison of Medtronic's Resolute and Abbott Laboratories' Xience V drug-eluting stents.

Monday, Nov. 7

11:20am-2:20pm / Endovascular Interventions (Part 1) / Session III. Emerging Approaches in Vascular Intervention (Room 131)

- 11:30am / *Twelve-Month Results from the COMPLETE SE Study of SFA Stenting*
- 11:55am / *Outcomes of Iliac Intervention Using a Co-Cr Balloon Expandable Stent: Final Results of the ACTIVE Study*

8:00am-6:00pm / Endovascular Intervention (Part 1) / Session III. Emerging Approaches in Vascular Intervention (Room 131)

- 1:30pm / *Deeper in the Pelvis: Status of Pudendal Artery Stenting for Erectile Dysfunction*

1:25-4:30pm / Valvular Heart Disease Summit / Session V: TAVR Evidence-Based Medicine Corner: Consensus, Gaps and

Controversies (Room 135)

- 2:05pm / *The Australia-New Zealand Multicenter TAVR Registry Experience*
- 3:38pm / *Updates from the US CoreValve Pivotal Randomized Trial*
- 4:01pm / *Self-Expanding CoreValve TAVR: Valve-in-Valve, Bicuspid Disease, an Aortic Regurgitation*
- 4:21pm / *SURTAVI*

8:00am-6:10pm / The Drug-Eluting Stent Summit: Appropriate Utilization of Current Generation Devices / Session VI. Emerging Noncoronary DES Applications (Room 104)

- 5:47pm / *Drug-Eluting Stents for the Treatment of Erectile Dysfunction: Results of the ZEN Trial*

6:00-7:00 pm / Special Twilight Session--Featured Clinical Research: TCV and STEMI/Heart Failure Therapies (Room 121)

- 6:15pm / *CoreValve Subclavian: A Single-Center, Propensity-Case-Controlled Registry of Transcatheter Aortic Valve Implantation via Subclavian vs. Transfemoral Access*

Tuesday, Nov. 8

10:15am-12:30pm / Drug-Eluting Stents II (Room 111)

- 10:15am / *Final 5 Year Follow-up from the RESOLUTE First in Man Trial*

10:15am-12:30pm / Intersection of Diabetes and PCI (Room 110)

- 10:28am / *One-Year Outcomes in Over 1,500 Patients with Diabetes Treated with the Resolute Zotarolimus-Eluting Stent*

10:15am-12:30pm / Transcatheter Aortic Valve I: Oral Scientific Session (Room 131)

- 10:41am / *Short and Long-term Safety and Effectiveness of Transcatheter Aortic Valve Implantation in a Failing Surgical Aortic Bioprosthesis*

10:15am-12:30pm / Transcatheter Aortic Valve II: Oral Scientific Session (Room 132)

- 10:28am / *TAVR for High-risk Patients with Severe Aortic Stenosis Who Satisfy All the Criteria for Conventional Aortic Valve Replacement: A United Kingdom-Based Cost-Utility Analysis Discussion*
- 11:46am / *Twelve-month Results from the CoreValve Transcatheter Aortic Valve Australia-New Zealand Study*

10:15am-12:30pm / Drug-Eluting Stents I and Bioabsorbable Scaffolds (Room 125)

- 10:54am / *The "Final" Five-Year Follow-up from the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with A*

Paclitaxel-Eluting Stent

10:15am-12:15pm / Predictors and Prevention of Stent Thrombosis (Room 124)

- 11:07am / *Pooled Analysis of RESOLUTE Clinical Trial Long-term Safety Data*

10:15am-12:30pm / Endovascular Intervention (Room 112)

- 11:46am / *From US Pivotal Study to 1,200 Patients on 6 Continents: A Global Perspective on the Endurant Stent Graft*

1:00-6:20pm / Device-Based Approaches for Heart Failure: Recent Developments and New Directions / Session II. Update on Novel Therapies for Heart Failure (Room 123)

- 2:33pm / *Renal Nerve Ablation (Ardian): Potential for Heart Failure*

4:00-6:00pm / Deep Dive: Interventional Hypertension / III. Interventional Hypertension Therapy (Room 135)

- 4:15pm / *Latest Results from Renal Denervation Therapy in Refractory HTN: The Symplicity HTN-1 and Symplicity HTN-2 Trials*
- 4:30pm / *Lessons Learned and Trial Design for the U.S. Pivotal Symplicity HTN-3 Trial*

Wednesday, Nov. 9

2:00-3:30pm / Surgical, Interventional & Hybrid Procedures (Room 133)

- 2:16pm / *If Transfemoral is Not Available, Alternative Vascular Access is Preferable to Transapical*
- 3:00pm / *TAVR:Parade of Next Generation Devices*

Thursday, Nov. 10

8:00-11:00am / Morning Spotlight Sessions: Next Generation Transcatheter Aortic Valve Therapies / Session I. New and Novel Transcatheter Aortic Valve Systems (Room 135)

- 8:34am / *Results from the Engager Transapical TAVR System*(formerly Ventor Embracer)

2:00-6:00pm / Drug-Coated Balloons: Clinical Data and Applications / Session I. Specific Devices and Latest Results (Room 133)

- 3:03pm / *Invatec: Technology Overview and Latest Peripheral Data*
- 3:13pm / *Invatec: Latest Coronary Data*
- 3:21pm / *Discussion with Audience Q&A: Critical Appraisal of the Invatec Technology and Results*

Friday, Nov. 11

11:00am-1:10pm / Plenary Session XXI. Late Breaking Clinical Trials and First Report Investigations III / Focus on Optimal PCI (Esplanade Ballroom)

- 11:55am / *TWENTE: A Prospective, Randomized Trial of Zotarolimus-Eluting Stents and Everolimus-Eluting Stents in Patients with Coronary Artery Disease*

Details such as times, titles and locations are subject to change.

The Resolute DES, IN.PACT DEB, CoreValve System and Symplicity System are all investigational devices in the United States, where their use is limited by U.S. law to clinical studies approved by the FDA. The Endeavor DES, Complete SE and Assurant Cobalt stents, and Endurant stent graft have all obtained FDA approval and are commercially available for clinical use in the United States.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE: Medtronic, Inc.

Medtronic, Inc.
Kathleen Janasz
Public Relations
763-526-3676
or
Joseph McGrath
Public Relations
707-591-7367
or
Jeff Warren
Investor Relations
763-505-2696

---

https://news.medtronic.com/2011-11-04-Medtronics-Unmatched-Portfolio-of-Cardiovascular-Devices-Features-Prominently-on-Program-for-TCT-2011